Skip to main content
. Author manuscript; available in PMC: 2018 Oct 30.
Published in final edited form as: Chem Soc Rev. 2017 Oct 30;46(21):6470–6479. doi: 10.1039/c7cs00472a

Fig. 2.

Fig. 2

(A) Molecular structures of EISA precursor 1 and the self-assembling molecule 2 after dephosphorylation. (B) Illustration of the pericellular nanofibrils of 2 formed via EISA to selectively inhibit cancer cells in co-culture by activating cell death signaling. (C) Molecular structure of the tyrosine-cholesterol conjugate 3 which converts into 4 upon ALP treatment. (D) TEM image of the nanoparticles formed by adding ALP into 3. (E) The IC50 (48 h) values of 3 against a platinum-resistant ovarian cancer cells (A2780cis) compared with clinic drug cisplatin. (F) Chemical structures of the ligand (Van) and receptor 5 containing D-Ala-D-Ala. (G) The ligand–receptor interaction-catalyzed molecular aggregation. Adapted with permission from ref. 13, 16 and 24. Copyright 2016, American Chemical Society (ref. 13). Copyright 2017, Nature Publishing Group (ref. 16). Copyright 2015, American Chemical Society (ref. 24)